Table 5.

TRAEs in 26 converted patients

TRAEs	Any grade    (n, %)	Grade1~2    (n, %)	Grade≥3   (n, %)
Hypertension	1 (3.8)	0 (0)	1 (3.8)
Decreased appetite	3 (11.5)	3 (11.5)	0 (0)
Abdominal pain	3 (11.5)	3 (11.5)	0 (0)
Nausea	2 (7.7)	2 (7.7)	0 (0)
Elevated alanine aminotransferase, ALT	16 (61.5)	12 (46.2)	4 (15.4)
Elevated aspartate aminotransferase, AST	19 (73.1)	13 (50)	6 (23.1)
Elevated blood bilirubin	13 (50)	12 (46.2)	1 (3.8)
Hypothyroidism	3 (11.5)	3 (11.5)	0 (0)
Palmar-plantar erythrodyses-thesia syndrome	2 (7.7)	2 (7.7)	0 (0)
Fatigue	1 (3.8)	1 (3.8)	0 (0)
Low leucocyte amount	3 (11.5)	2 (7.7)	1 (3.8)
Neutrocytopenia	1 (3.8)	1 (3.8)	0 (0)
Thrombocytopenia	7 (26.9)	5 (19.2)	2 (7.7)
Oral mucositis	1 (3.8)	0 (0)	1 (3.8)
Rash	1 (3.8)	1 (3.8)	0 (0)
ICIs-associated myocarditis	1 (3.8)	0 (0)	1 (3.8)
RCCEP	1 (3.8)	1 (3.8)	0 (0)

TRAEs Treatment-related adverse events, ICIs Immune checkpoint inhibitors, RCCEP Reactive cutaneous capillary endothelial proliferation